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INTRODUCTION 
 
Background: 
 
It is reported that more than 10-20% of women in the United States have sexual health 
problems involving desire, arousal, orgasm, and/or pain associated with personal distress 
or bother. Historically, these issues were managed primarily by mental health professionals 
and were largely ignored by the medical community.  Male sexual dysfunction, on the other 
hand, found its place within the field of urology. With the advent of the FDA approved 
sildenafil as a safe and effective treatment for men with erectile dysfunction in 1998, 
women began seeking medical attention and demanding equal therapies for their own 
unaddressed sexual health concerns.  
 
Female sexual medicine is a field that lends itself extremely well to a multidisciplinary 
model, though its current place within the traditional realm of medicine is largely 
undefined. While it has become acceptable for a man to present to his primary care 
physician or urologist with an issue regarding his sexual health, women are often 
misdiagnosed or ignored by medical professionals who are unfamiliar with management 
strategies for female sexual dysfunction. This divergence might stem from the fact that 
sexual medicine is not currently included in most medical school curricula. As a result, 
general medical practitioners are often not trained in or comfortable with managing sexual 
health issues, especially for their female patients.  
 
While this exciting new field is continuously evolving and expanding, standards of care are 
already being implemented where the need for such a field has gained favor. A gynecologist, 
primary care physician, internist or psychologist is the current first line of intervention for 
women seeking initial management for their sexual health issues. The sexual medicine 
physician may be an appropriate second line of intervention if further management or 
expertise is needed. Some sexual medicine treatment facilities have even evolved to 
incorporate sex therapy and physical therapy under the same roof in order to evaluate the 
complex and multifactorial origins of these presenting problems comprising a 
biopsychosocial model. 
 
Primary care physicians may be an appropriate first stop for women with a sexual health 
concern. These physicians often have longitudinal relationships with their patients and can 
review medications and overall health, screen for diabetes or depression, ask lifestyle 
questions and test blood levels that could be contributing to sexual health problems.  
 
For a woman seeking medical attention regarding her sexual health, however, the 
gynecologist is a popular first choice.  Within this field, gynecologists with a special interest 
in vulvar and sexual health issues may have extensive experience in diagnosing and treating 
vulvar conditions, including vulvodynia, vulvar vestibulitis, vulvar itching and chronic 
vaginitis, along with pain during intercourse or lack of desire. Additionally, gynecologists 
with a focus on menopausal women often hear concerns related to sexual dysfunction from 
their patients.  
 
Referral to a sexual medicine specialist may be indicated if further expertise in diagnosing a 
sexual health concern is felt appropriate. Sexual medicine physicians, usually board-
certified in urology or OB/GYN and specially trained in sexual and reproductive 
dysfunction, approach sexual concerns mainly through the biopsychosocial model. This line 
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of thinking suggests that almost all concerns are a combination of psychological and 
physical factors; psychological issues will eventually have physical ramifications and 
physical problems will have psychological ramifications. Management of these concerns 
require the multidisciplinary model, in which the sexual medicine specialist will provide a 
comprehensive evaluation, follow-up and surgical intervention if needed. Female sexual 
health problems treated by a sexual medicine specialist may include libido, lubrication or 
orgasm problems, and sexual pain disorders.   
 
Sex therapists are often part of the multidisciplinary team in sexual medicine. These 
specialists may address the sexuality, relationship and intimacy concerns of individuals or 
couples who may visit a sexual medicine physician. If indicated, psychotherapy for 
individuals, couples and families may be used.  
 
Pelvic floor physical therapists are also often vital in helping to diagnose a sexual health 
issue. Common problems seen by these specialists include urinary incontinence, pelvic pain, 
dyspareunia and vaginismus, vulvodynia and vestibulodynia, pudendal nerve pathology, 
endometriosis, and prenatal and postpartum care.  
 
Description of project/goals/objectives: 
 
Sexual medicine, a field dedicated to human sexuality and its disorders, derives its clinical 
success from a multidisciplinary approach to care. Treatment facilities focusing solely on 
sexual medicine are rare, so the opportunity to dedicate my summer exploring the 
biopsychosocial model for women in this setting is quite unique.  
 
My overall goal for this ISP is to explore the physiological, musculoskeletal and 
psychological aspects of female sexual medicine from varying perspectives and 
management approaches in order to better care for a woman with sexual health concerns. 
As a first-year medical student with a passion for exploring a field not yet well defined 
within the traditional medical realm, I believe this unique opportunity will provide me with 
an experience that I would not otherwise be exposed to during my time in medical school.  
 
My specific aims for this project are as follows: 
1) To understand the biopsychosocial origins of a woman presenting to a sexual 
medicine specialist or OB/GYN with a sexual health concern 
2) To gain insight into the different perspectives and management approaches 
provided by a multidisciplinary team 
3) To compare the different practices providing care for female sexual dysfunction 
4) To understand the path that female patients take to seek care for their sexual 
dysfunction 
5) To understand the barriers of discussing female sexual health with a given provider 
and seeking care from the patient’s perspective 
6) To understand what a comprehensive evaluation for a woman presenting with a 
sexual health concern entails 
7) To gain insight into what role a woman’s partner may play in the initial 
presentation, diagnosis and management of female sexual dysfunction 
8) To assess what the female patient’s goals and expectations are for treatment  
9) To evaluate the female patient’s perception of her experience based on management 
by a multidisciplinary team including physician, sexual therapist and physical 
therapist at a single site 
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10) To gain insight into the novel techniques and evaluation methods being utilized for 
diagnosing female sexual dysfunction 
 
Personal background & motivation 
 
Female sexual health is a relatively new and widely unexplored area of medicine. Growing 
up in an open-minded Brazilian family, the subject of sex was not considered taboo and as a 
result I have always felt comfortable openly discussing this topic. It was not until I became 
the confidant with friends about their sexual concerns at a young age that I realized many 
women do not feel comfortable bringing up these issues with their healthcare providers. 
During my first year of medical school at UC-San Diego School of Medicine, I was able to 
begin exploring this field professionally. I began shadowing Dr. Irwin Goldstein, an expert 
on the topic of male and female sexual dysfunction, at San Diego Sexual Medicine during the 
winter and spring term. I was especially interested in the topic of female sexual dysfunction, 
a branch of medicine not yet well defined within the traditional medical realm.  
 
Through my clinical exposure to the multidisciplinary biopsychosocial evaluation of a 
woman presenting with a sexual health concern, I will be able to better understand the 
biopsychosocial origins and manifestations of women presenting with sexual health 
concerns. I hope to gain insight into the barriers that prevent women from initially seeking 
care, the path they take to finally receive care, and what resources and are currently 
available for women with sexual dysfunction.  
 
 
RESULTS/CLINICAL EXPERIENCE 
 
To complete my FCM-ISP, I spent the summer of 2015 with Dr. Irwin Goldstein at San Diego 
Sexual Medicine (SDSM), Dr. Kathryn Macaulay at UCSD’s Menopause Health Program, and 
Dr. Erin Gross at UCSD’s Vulvar and Sexual Pain Clinic. I gained clinical exposure with a 
multidisciplinary team including a sexual medicine urologist, sex therapist, pelvic floor 
physical therapist, and nurse practitioners for the comprehensive evaluation of women 
presenting with sexual dysfunction.  
The most common patient presentations across these three sites were perimenopausal or 
menopausal women seeking care for vasomotor and/or sexual dysfunction symptoms. In an 
effort to compare the varying treatment approaches, I will first provide background for the 
hormonal explanation of Genitourinary Syndrome of Menopause (GSM), followed by 
summaries of my experience with each provider and a representative case presentation at 
each site. In addition, I will present the research I completed during my time at San Diego 
Sexual Medicine studying the vulvoscopic findings of menopausal women presenting with 
sexual dysfunction pre- and post- hormonal treatment. I received the 2016 Sexual Medicine 
Society of North America (SMSNA) Scholars in Sexuality Research Grant to complete this 
research project, and became the primary author of a podium presentation at the SMSNA 
2016 Annual Fall Scientific Meeting in Scottsdale, Arizona, with my abstract published in 
The Journal of Sexual Medicine. 
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Through my experience at SDSM with Dr. Goldstein, I also gained exposure to the surgical 
management of sexual dysfunction. To describe the impact of surgical intervention once 
medical management options were exhausted, I will present a patient testimonial.   
 
Background of GSM: 
Serum estradiol values vary widely in a woman’s life.  Prior to puberty, serum estradiol 
values are low.  Post-puberty, during reproductive ages, women have variations in serum 
estradiol that range from approximately zero to approximately 500 pg/ml every 28 days.  
Two estradiol peaks are noted: at ovulation and in the mid-luteal phase.  During pregnancy 
serum estradiol values rise to approximately 2,000 - 3,000 pg/ml. In the peri-menopausal 
transition starting at age 40 years, there are progressive reductions in peak serum estradiol 
during increasingly irregular menstrual cycles. The overall decline in peak serum estradiol 
leads initially to hot flashes and night sweats. Menopause is characterized by the cessation 
of ovarian estradiol synthesis. Typically occurring in women in midlife, during the early 50s, 
natural menopause is defined as beginning a year after their last menstrual period in those 
women who have not had a hysterectomy. Surgical menopause occurs after women have 
had bilateral oophorectomy.  Over time, continuous estradiol loss causes up to 45% of 
menopausal women to experience symptoms of vaginal atrophy, including dryness, 
dyspareunia, involuntary urination, soreness, itching, burning and pain.   
 
Serum testosterone values (ng/dl) in women decline progressively after age 30, so there are 
no distinct changes at the perimenopause in serum testosterone comparable to estradiol.  
Sex hormone binding globulin values increase during aging and following exposure to 
medications such as hormonal contraceptives and oral estrogens.  Free or calculated free 
testosterone thus falls more progressively at a steeper slope than serum testosterone.  
Perimenopausal and menopausal women also experience a decline in serum testosterone, 
in part a result of the declining production of testosterone pro-hormones, 
dehydroepiandrosterone, by the adrenal glands. Despite a contribution to serum 
testosterone levels by the ovaries in post-menopausal women, the ovaries are not usually 
able to correct the deficit in the adrenal glands’ production. Symptoms of “female androgen 
insufficiency syndrome” include diminished sense of wellbeing or dysphoric mood, reduced 
muscle and bone mass, and decreased sexual desire, arousability, and pleasure.   
 
Serum progesterone values (ng/ml) during the reproductive years increase post-ovulation 
as progesterone is synthesized in the corpus luteum during the luteal phase.  When ovarian 
ovulation begins to fail in perimenopausal women, serum progesterone values approach 
zero ng/ml. 
 
The collection of symptoms and signs associated with a decrease in serum sex steroid 
hormones, estradiol, progesterone and testosterone, involving physical changes to a 
woman’s genitourinary region is now described by the comprehensive term, GSM. 
 
The prevalence of female sexual dysfunction in menopausal women, low desire, low arousal, 
poor orgasm and dyspareunia, has been estimated to vary from 25% to 63% of women.  In 
the community, treatments for the various female sexual dysfunctions in menopause have 
varied widely, from use of local vaginal creams to systemic estradiol and progesterone 
administration.   
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UCSD Menopause Clinic – Dr. Kathryn Macaulay 
 
During my time with Dr. Macaulay, I gained exposure to peri- and menopausal women 
seeking treatment for vasomotor symptoms. Oftentimes, these women admitted to 
concomitant dissatisfaction with their sexual life related to low libido, vaginal dryness or 
pain with intercourse. Sexual function was screened for during intake of menopause 
consultations, and areas of concern were discussed openly during visits. In addition, Dr. 
Macaulay has extensive experience with hormone replacement therapy, and spends the 
necessary time with patients to discuss the indications, benefits and risks so that they can 
make a shared and educated decision.  
 
The unexpected findings of the Women’s Health Initiative (WHI) study in 2002 
demonstrating an increased risk of stroke, heart attack, blood clots and breast cancer 
radically changed physicians’ understanding of the benefits and risks of hormone therapy. 
Prior to that, several published observational studies, reviews, and meta-analyses suggested 
that postmenopausal hormone replacement therapy (HRT) actually reduced the risk of 
coronary heart disease, in that estrogen was found to raise HDL and reduce LDL. Many 
women are still cautious to use HRT after the WHI trial came out, with hormone therapy use 
by women in their 50s declined by 60% from 2001 to 2009.  
 
However, subsequent evidence has demonstrated that these findings may be limited to the 
certain formulations of HRT used in the WHI trial. These include the effects of oral 
conjugated equine estrogens (Premarin) rather than transdermal estradiol and oral 
medroxyprogesterone acetate rather than oral micronized progesterone. Using transdermal 
estrogen would bypass the first-pass effect of oral formulas, inhibiting the undesirable 
metabolic effects including elevated triglycerides, decreased LDL particle size, and 
increased production of coagulation factors and CRP which could be factors contributing to 
heart disease in the WHI.  According to the most recent position statement from the North 
American Menopause Society (NAMS), oral estrogen +/- progesterone therapy increases the 
risk for ischemic stroke by about 1/3 in relatively healthy postmenopausal women. 
Transdermal estradiol at a dose of 50 micrograms or less did not increase stroke risk. 
Furthermore, growing evidence suggests that women with a history of VTE or those with 
Factor V Leiden mutation are at increased risk for VTE with HT use. Limited observational 
data suggest lower VTE risk with transdermal versus oral ET, but no comparative RCT data 
are available. Finally, several studies have shown that oral micronized progesterone has an 
overall better risk profile than other progestins with regard to thrombotic and breast 
cancer risks.  
 
The debate regarding hormone replacement therapy has brought about the importance of 
individualized therapy to treat menopausal symptoms, considering a patient’s risk factors 
with the goal to use the lowest effective dose for the shortest period of time. Currently, 
NAMS advises that indications for using systemic hormone replacement therapy are for 
treatment of moderate to severe vasomotor symptoms that are bothersome to the patient. 
Hormone therapy initiation by women aged 50 to 59 years or by women within 10 years of 
menopause to treat typical menopause symptoms does not seem to increase the risk of 
coronary heart disease events; and in fact, started early in menopause may reduce the risk.  
There is a general consensus within the medical community that HRT may be helpful in 
preventing osteoporosis, reducing the risk of colon cancer and benefiting urinary health.  
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Case Study C.R. 
 
Subjective 
48 year old G3P2 referred for a new menopause consultation. Patient reported a history of 
menorrhagia with endometrial ablation in 2007. Menopausal symptoms began within the 
past year, including hot flashes every 1-2 hours, night sweats and insomnia (only sleeping 
4-5 hours/night). She complains of increased vaginal dryness and pain during intercourse, 
but otherwise denies issues with partner with sex. Patient reported depression and poor 
mood since the beginning of the year. Has been followed by a therapist which has been 
somewhat helpful but has not started medications and not interested in starting any.  Tried 
testosterone cream for libido last year for 3 months. Tried a “hormonal pill” unsure the 
name for 2 days but stopped secondary to palpitations. No risk factors for osteoporosis, or 
breast cancer other than age. Father has had 4 myocardial infarctions, first at age 55. Pap 
testand Mammogram both had normal findings. She never had a DEXA or colonoscopy 
performed.   
 
Objective 
Labs showed normal CBC, CMP, low serum testosterone (3 with range 8-48), free 
testosterone 0.6 (0.0-2.2 F), estradiol < 6.0, LH 41.2, FSH 121.5, TSH 1.28, FT4 1.05 
 
Assessment  
Patient is a candidate for postmenopausal hormone therapy for treatment of moderate-
severe vasomotor symptoms. Discussed with patient current indication for using HT is for 
treatment of moderate to severe vasomotor symptoms that are bothersome to patient and 
to use lowest effective dose for relieving symptoms. The need for continuing use of 
hormone therapy will be reassessed periodically, at least annually. Discussed studies 
showing increase in risk of breast cancer with combination E/P use, particularly if used for 
longer duration (>5 yrs). Also increased risk of DVT/PE and small increase in risk of stroke 
was discussed.  
 
Plan 
Rx given: transdermal estrogen patch, Vivelle 0.05 mg 2x/week—start for 4 weeks then add 
in progesterone. Prometrium 100mg/d po daily to start 1 month after using patch for 
endometrial protection. F/U in 3 months 
 
Follow-up at 3 months:  
Improvement in hot flashes since starting estradiol patch, denies vaginal bleeding and uses 
lubricants for vaginal dryness 
No libido or sexual desire and no sex for 2 months—new symptom for her since 
menopause. Testosterone cream in the past led to no improvement in libido. Has tried 
therapy in the past, stress over low libido and worried how it’s affecting her relationship. 
Living together with her boyfriend and interested in trying flibanserin, doesn’t drink 
alcohol.  Assessment was hypoactive sexual desire disorder causing personal distress with 
no other identifiable reasons for low sexual desire. Rx flibanserin 100 mg. Advised patient 
of side effects including hypotension, syncope which is increased with interaction with 
alcohol. Signed REMS program patient-provider agreement form regarding interaction of 
flibanserin with alcohol.  
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UCSD Vulvar Pain Clinic – Dr. Erin Gross  
 
Dr. Gross provides special care for patients experiencing vulvar pain or issues related to 
sexual desire or function. It is important to note that many women with chronic vulvar pain 
are told their symptoms are “all in their head.” Lack of diagnosis can further increase 
distress and delay access to more specialized medical care.  
 
Vulvodynia is a common chronic pain disorder localized to the vulvar region, lasting at least 
3-6 months, and thought to affect 15-20% of adult women. It is often associated with 
varying pain intensities and triggers, and can sometimes be episodic, intermittent or 
unremitting. If vulvar pain is localized to the vestibule, it is commonly called vestibulodynia 
or vulvar vestibulitis syndrome. The origin is thought to be either hormone-mediated or 
neuroproliferative, meaning it is a problem of too many skin nerves in small zones. Theories 
include increased local inflammation factors like histamines and substances, which keep the 
capillaries dilated and increase the nerve endings. Another theory is that estrogen receptors 
disappear and this somehow signals the extra nerves to grow.  
 
On physical exam of the pelvic floor, women with vulvodynia have increased spasm and 
tone of the levator ani muscle in response and compensation to vulvar pain. Biopsies have 
shown more areas of chronic inflammation and more pain nerve fibers. The underlying 
cause may be attributed to inflammatory and infectious disease processes, neurologic 
conditions, genetic factors, stress factors and hormone factors. Known medical causes 
include vulvovaginal candida or yeast infections, endometriosis of the vulva, lichen sclerosis 
or lichen planus, contact dermatitis of the vulva, vulvar atrophy from low levels of sex 
steroid hormones, pudendal nerve entrapment syndrome, referred pain from tender pelvic 
floor muscles, post-op pain after perineal surgery, or following perineal radiation therapy. 
Risk factors for the development of vulvar pain include irritable bowel syndrome, 
interstitial cystitis or oral contraceptive pills.  
 
Dr. Gross utilizes a multidisciplinary approach in the management of vulvodynia, utilizing 
referral to pelvic floor physical therapy, pain clinic, or sexual therapy. Central nervous 
system sensitization is often center to visceral and somatic hypersensitivities and 
hyperalgesias, so attention to the neuromuscular system is central to management. 
Treatment for vestibulodynia may include lidocaine ointment (applied just before 
intercourse with a cotton ball), tricyclic or SNRI antidepressants (Elavil 10 mg tablets daily 
increasing up to 50 mg q week), anticonvulsants (gabapentin 300 mg increasing up to three 
pills TID), steroid cream, biofeedback, pelvic floor physical therapy or nerve blocks. 
Typically, vulvar or vestibular “pain” indicates a likely contribution from low levels of sex 
steroid hormones whereas “itching” may be more related to inflammation and thus may 
respond better to localized steroid treatment. Only in menopause is estrogen therapy really 
helpful, as younger women have estrogen, but the tissues cannot sense it.  
 
 
Case Study: D.B. 
 
Subjective 
56 yo F with history of lichen sclerosis who presents with itching and burning of the vulva. 
Diagnosed with lichen sclerosis 1.5 years ago by vulvar biopsy. Has tried clobetasol 
intermittently, but complains of the sensation of “tearing” with sexual intercourse. She has 
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not looked in the mirror to assess skin changes. Denies vaginal bleeding or trauma to the 
perineum. Not on any hormone replacement therapy, denies hot flashes or night sweats.  
 
Objective 
Vulva Exam: Persistent pale plaques with evidence of fissuring most prominent at the 
posterior fourchette. 
Anus/Perineum: perianal involvement consistent with lichen sclerosus  
 
Assessment 
Lichen sclerosus is a skin disorder that affects the vulvar skin. It may occur in any age group 
of women and girls. The exact cause is unknown but it is not a contagious disease.  
Lichen sclerosus is characterized by small white patches that give the skin a crinkled 
appearance, looking like parchment paper. The skin can become red, thin, irritated, sore and 
typically itchy. Affected skin may involve the entire vulvar area from the clitoris to the anus. 
Eventually, scarring of the vulvar foreskin hides the clitoris. The labia minora may 
disappear almost completely at times. Not uncommonly, splitting of the skin in the midline 
is seen. Tears may also develop in the natural folds of the vulva. The vaginal opening may 
become smaller, interfering with intercourse. Scratching may lead to erosions. Itching and 
pain are the primary symptoms. Lichen sclerosus is associated with destructive 
architectural changes, difficulty voiding and inflammation. In addition, patients with lichen 
sclerosus typically have a higher risk of developing vulvar dysplasia. The difference 
between treatment for a symptom flare and maintenance therapy was also discussed. A 
biopsy is usually necessary to make the diagnosis.  
 
Lichen sclerosus is a chronic skin condition. Symptoms can be managed, but not cured. The 
goal of treatment is to eliminate symptoms and protect the skin from damage. Commonly, 
the anatomic changes of lichen sclerosus will not completely resolve despite persistent and 
aggressive treatment. Treatment usually requires the use of high potency topical steroids or 
other anti-inflammatory medications. 
 
Due to the chronic nature of the disease, diligence to treatment is important to protect the 
skin from further damage and to help control symptoms. Treatment will help prevent 
further changes in anatomy and preserve normal elasticity. Reexamination of the skin at 
least every six to twelve months is necessary to track changes and progression or 
regression of the disease. It is important for the women with lichen sclerosus to do vulvar 
self-examinations. This will allow her to track changes and monitor if any areas are not 
responsive to treatment or are chronically eroded.   
 
Plan 
-Continue clobetasol twice daily for 1 week then taper to nightly for maintenance therapy 
-Stressed the importance of six month interval visits given chronicity of disease  
-Begin using a vaginal estrogen, Estrace, twice weekly at night to restore vaginal moisture, 
flexibility and skin integrity  
-Discussed careful care of the vulva to help alleviate some symptoms of itching, burning and 
irritation including avoiding contact with irritating chemicals such as soaps, wearing 100% 
cotton underwear, not using sprays or powders on the vagina, not douching  
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San Diego Sexual Medicine – Dr. Irwin Goldstein  
Biological Female Sexual Medicine Evaluation 
 
At San Diego Sexual Medicine, treatment of women in menopause with female sexual 
dysfunction is based on a comprehensive evaluation of biopsychosocial contributors, 
including physical therapy, sex therapy and biology. Specifically, within biologic factors, 
hormonal managements of menopausal women are based on individual symptoms, patient 
reported outcomes, physical findings including vulvoscopy and regular monitoring of sex 
steroid hormone blood test values. The goal is to utilize biologically identical sex steroid 
hormones to achieve and maintain ideal values of: 1) serum testosterone (0.8 ng/dl), 2) 
serum estradiol (35 – 50 pg/ml), and 3) serum progesterone (1 ng/ml).  In addition, 
hormonal management engages: 4) local estradiol and testosterone treatment to the 
vestibule and 5) local estradiol and testosterone treatment to the vagina.   In total there are 
five hormonal-based treatments in menopausal management. 
 
 
 
Systemic biologically identical estradiol therapy that meets the goal of 35-50 pg/ml in our 
clinical experience has been shown to successfully improve hot flashes, night sweats, and 
sleep disturbances that negatively affect body image, mood, and sexual desire. Systemic 
biologically identical progesterone therapy that meets the goal of 1.0 ng/ml may add 
additional cognitive, bonding and wellbeing benefits and should always be used to oppose 
the effect of systemic estrogen in women with an intact uterus.  
 
Systemic biologically identical testosterone is not FDA approved for women but has been 
reported in the treatment of menopausal women for more than 50 years.  Nevertheless, 
recent randomized double-blind, placebo-controlled clinical trials in women in menopause 
have demonstrated that systemic biologically identical testosterone therapy significantly 
improves sexual desire, arousal, orgasm frequency and sexual satisfaction compared to 
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placebo. In addition, local vestibular testosterone and estradiol therapy have been shown to 
relieve symptoms of vulvovaginal atrophy and hormonally-mediated vestibulodynia. The 
vestibule is of endodermal embryology and has high concentration of androgen receptors. It 
is hypothesized that the improvement in vestibular pain after systemic and local 
testosterone therapy is seen in part because minor and major vestibular gland health and 
lubrication relies upon testosterone and other androgens.  
 
 
 
Case Study: M.G. 
Subjective 
45 year old G3P1021 perimenopausal female presents at initial consultation with symptoms 
of depression, low libido, fatigue, mood changes, forgetfulness, and hot flashes.  History of 
total hysterectomy in 2013, and multiple prior surgeries for endometriosis, fibroids, and 
ovarian cysts. Following hysterectomy, she was put on oral premarin which she recently 
stopped taking. Reports an intercourse success rate of 10%, engages in intercourse twice 
per week with low arousal and orgasmic capabilities.  
 
VALIDATED OUTCOME SCALES   
Total Desire Domain score: 1.2.  
Total Arousal Domain: 2.1.  
Total Lubrication Domain:3.6.  
Total Orgasm Domain:1.6.  
Total Satisfaction Domain: 2.4.  
Total Pain Domain:6.  
FSFI score: 16.9.  
SDS-R score: 29 /52.  
PHQ-9 score: 21.  
PSS score:28/40.  
Sensory score:19 /33.  
Affective score: 5/15.  
PPI score: 0 /5.  
V-Q: 10.  
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Objective 
Labs show vitamin D of 25.9, TSH of 0.926, total T of 11, SHBG of 240.3, prolactin of 9.7, 
progesterone of 0.3, FSH of 52, LH of 64.7, estradiol of 47.3, DHT of 7.4, and calculated free T 
of 0.0418.  
 
Vulvoscopy:  
Her right labia majora was normal. Her left labia majora was normal. The right interlabial 
sulcus was normal. The left interlabial sulcus was normal. The clitoris was 1/2 size. The 
clitoral hood was normal. The frenulum on the right side was normal. The frenulum on the 
left side was normal. The width of the labia was 15 mm on the right and 20 mm on the left. 
There was 50% resorption of the right minora in the posterior aspect of the vestibule. There 
was 25% resorption of the left minora in the posterior aspect of the vestibule. Both labia 
minora did not meet at the posterior fourchette. The urethral meatus was normal.  
The minor vulvar vestibular glands at 1 o’clock, 3 o’clock, 5 o’clock, posterior fourchette, 7 
o’clock, 9 o’clock and 11 o’clock revealed erythema with the 1 o’clock, 3 o’clock, and 11 
o’clock areas with 5/10, 5/10, and 2/10 discomfort to cotton swab testing, respectively.  
Speculum examination was performed. Vaginoscopy revealed minimal rugae. The color of 
the vaginal wall was normal. There was normal discharge. The vaginal pH was 4.5 as 
measured by pH paper. This study revealed clitoral atrophy, labial resorption, and mild 
provoked vestibulodynia.  
 
Assessment  
Discussed M.G’s elevated SHBG likely due to oral premarin use leading to a low calculated 
free testosterone (1/20 the ideal value of 0.8 ng/dl), consequences of which include low 
libido, pain during intercourse, mood changes, low energy, and inability to achieve orgasm. 
Discussed the five treatments for menopausal management, including systemic 
testosterone, estradiol, progesterone and local vestibular and intravaginal hormonal 
therapy. Options for testosterone therapy include a daily topical gel, intramuscular 
injections weekly into the thigh or a subcutaneous pellet placed every 4-6 months. For 
estradiol therapy given E2 values below goal of 35-50, M.G. is considering transdermal 
patch, IM injections or a vaginal ring. For progesterone therapy given goal of 1, we 
discussed use of oral micronized progesterone. Concerning hormone mediated provoked 
vestibulodynia and vulvovaginal atrophy, M.G will use daily compounded formula of 
estradiol and testosterone topical gel. 
 
Concerning low sexual interest, the problem seems to be, in part, related to an imbalance of 
excitatory and inhibitory neurochemicals in the portions of the brain where the sexual 
reflexes are regulated. We discussed high inhibition, low excitation sexual dysfunction and 
general strategies to improve libido. Specific strategies to manage low libido include 
dopamine agonists, oxytocin, amphetamine, PDE5 inhibitors, serotonin antagonists, opioid 
antagonists, and progesterone. As there are no current FDA-approved therapies for this 
sexual disorder, we discussed that these therapies vary by the individual, so it may take 
some experimenting to find a therapy that works for her. These strategies often work 
synergistically with other therapies, so we will follow M.G’s hormones to find balance.  
 
Plan 
1. Testosterone replacement: 1 testosterone pellet (75 mg Testopel) placed 
subcutaneously, midway between right iliac crest and right sacroiliac joint  
2. Estradiol replacement: Systemic biologically identical estradiol replacement with 
Femring 0.05 mg 
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3. Progesterone replacement: Biologically identical micronized progesterone 100 mg 
twice weekly, on Monday and Thursday 
4. Vestibular and intravaginal therapy: Administer daily low dose biologically identical 
compounded estradiol 0.03% and testosterone 0.1% gel to the vestibule. 
5. Vitamin D supplementation: Start vitamin D3 5,000 IU daily 
6. Get labs (testosterone, estradiol, progesterone, SHBG, DHT, Vitamin D) redrawn in 
4-6 weeks, with follow-up 1 week after labs done 
7. For low sexual interest, consider sex and physical therapy, along with 
experimenting with bupropion 75 mg daily in the morning to raise dopamine, 
oxytocin 250 IU lozenge an hour prior to intercourse, Viagra 25 mg one hour prior 
to intercourse or Buspar 10 mg daily to lower serotonin  
 
Psychological Sex Therapy 
 
Sex therapy provides a forum where all of the contributions to sexual difficulties can be 
identified and addressed with the woman alone or with her partner.  While diminished 
sexual desire or sexual apathy is the most prevalent sexual complaint of women, orgasmic 
problems are common as well. Women with these difficulties may experience more sexual 
guilt, be less sexually assertive, and endorse more negative attitudes towards sexual activity 
and masturbation. Therapy is typically brief, often no more than 10-12 sessions, but focused 
on individualized care.  
 
Dr. Hartzell at San Diego Sexual Medicine is a marriage and family therapist who focuses on 
relationship issues that may be preventing an individual or couple from having a more 
fulfilling sex life. She helps patients to gain a deeper understanding of their own sexuality 
and how it affects their lives and relationships. In addition, she helps individuals and 
couples learn how to communicate their sexual needs and desires to deepen their sexual 
lives.  
 
There are several predisposing, precipitating, maintaining, and contextual factors that come 
into play when evaluating sexual discontent and difficulties. Negative early life experiences, 
including sexual, physical or emotional abuse may predispose to later sexual problems. 
Precipitating factors include repetitive or traumatic sexual experiences that may damage 
self-confidence such as repeated criticisms from a spouse or discovery of a partner’s 
infidelity. Finally, maintaining factors such as relationship distress, inadequate sexual 
stimulation, anxiety and depression, or impaired self-image or self-esteem may prolong and 
exacerbate problems, irrespective of the original predisposing or precipitating conditions. 
Contextual factors are included in maintaining factors, in that they can interfere or interrupt 
sexual activity such as anger or resentment towards a partner.  
 
Case Study: M.G. 
M.G. states that 6 months after starting premarin in 2013 after a total hysterectomy she 
noticed mood changes including depression, low libido, fatigue, forgetfulness and feeling 
“off balance”. These symptoms have worsened in the past year. Regarding psychological 
treatment in the past, she has a short history of taking Lexapro for 2 years during the 
postpartum period. Felt this was helpful at the time, but was able to wean off without issue.  
 
Currently feels that these hormonal changes are emotionally distressing, including weight 
gain, dry skin, and body aches. She uses Xanax occasionally for anxiety, minimal social 
alcohol use and denies recreational drug use. 
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Regarding her sex life, she feels no sexual urges. She has a loving husband of two years, and 
they engage in intercourse but only because she wants to help participate (husband with 
erectile dysfunction). She admits to a history of molestation by her uncle as a child. In 
addition, her current husband’s ex-wife is harassing her and patient’s ex-husband was 
emotionally abusive.  
 
Provided supportive counseling for patient, and discussed possible contribution of patient’s 
abusive past to current sexual dysfunction. Recommend continued counseling to work 
through trauma from past. The technique of cognitive behavioral therapy (CBT), may be 
especially helpful to understand if and why she is avoiding sexual activities, what role she 
and/or her partner play, and exploring potential solutions or options for physical intimacy. 
 
Pelvic Floor Physical Therapy 
 
Pelvic floor physical therapists provide personalized treatment to restore function, improve 
mobility relieve pain and prevent or limit permanent physical disabilities of patients 
suffering from injuries or disease. Their specialization is in pelvic floor disorders, including 
urinary dysfunction such as incontinence and organ prolapse. Physical therapists provide 
education, anatomical and physiological information and give specific exercises with the 
goals of decreasing vaginal pain and sensitivities of painful tissues. Pelvic floor hypertonus 
or high muscle tone may also contribute to sexual pain and an important part of physical 
therapy is teaching the patient how to normalize muscle tone. 
 
Debbie Cohen is a pelvic floor physical therapist, and is certified in exercise science, 
orthopedic manual therapy of the spine, and women’s pelvic health. Her evaluation and 
therapy intervention generally consist of education, pelvic floor strengthening exercises, 
and utilizing the modalities of pelvic floor biofeedback and electrical stimulation. Ms. Cohen 
also has a personal interest in preventive health and advocates for healthy lifestyle changes 
in her patients, including regular aerobic exercise, practicing daily pelvic floor relaxation 
and good urinary habits, along with eating a whole foods diet to promote a healthy 
microbiome.  
 
Case Study: M.G. 
Goal of consultation to establish mind-body awareness. Approach from abdominal muscles, 
feeling mobility of scar tissue, relaxing transverse abdominal and internal oblique muscles. 
Inside vagina, identified areas of restriction from scar tissue and areas of sensitivity. Feel for 
pelvic floor prolapse, laxity of tissue not supported by uterus. Discussed that shallow 
muscles inside the vagina are responsible for stopping the urine stream.  
 
Educated patient regarding the pelvic and structural anatomy for a better understanding of 
the functions of each muscle and how malfunction may lead to pain or sexual dysfunction.  
The perineum is a diamond-shaped area, subdivided into an anterior part, the urogenital 
triangle (UGT) and the posterior part, the anal triangle. 
 
The UGT contains the superficial muscles of the perineal region, known as the first layer. 
These include the superificial transverse perineal (stabilizes the perineal body), 
bulbocavernosus (functions as a vaginal sphincter and assists in erection of the clitoris), 
ischiocavernosus (clitoral erection). The anal triangle consists of the external anal sphincter 
(part of voluntary sphincter of anal canal).  
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The second layer of the UGT is enveloped by the superior and inferior fascia, and contains 
the urogenital diaphragm (UGD). The UGD consists of 3 layers, the inferior layer of fascia 
known as the perineal membrane, a muscle layer containing the sphincter urethrae and the 
deep transverse perineal muscles. The UGT and UGD are innervated by the pudendal nerve, 
3 branches in the superficial and deep layers including the dorsal nerve of the clitoris, the 
perineal branch and the inferior hemorrhoid nerve or inferior rectal nerve.  
 
The third layer involves the levator ani consisting of the pubococcygeus (pubovisceral, 
pubovaginalis) which supports the pelvic viscera, puborectalis which acts as the voluntary 
sphincter of the anal canal, and iliococcygeus which supports the viscera and lateral coccyx.  
 
 
 
Performed surface EMG muscle biofeedback, in which a sensor is placed in the vagina and 
the muscle activity of the pelvic floor is recorded and displayed on a computer monitor. 
With this visual feedback, the woman is able to see how tense or weak her muscles are and 
this allows her to learn the proper methods to relax and strengthen her muscles. 
Established a baseline at rest then isolated different muscles with a series of contractions 
and relaxations. From shallow to deep, targeted muscles include the bulbocavernosus, 
ischiocavernosus, superficial transverse perineal, deep transverse perineal, levator ani 
(pubococcygeus, puborectalis, iliococcygeus) and coccygeus muscles.  
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Research 
 
Specific Aims and Hypothesis 
The primary objective of this study is to evaluate the clinical benefit of hormonal strategies 
for the management of sexual dysfunction and Genitourinary Syndrome of Menopause 
utilizing pre- and post-treatment vulvoscopic findings with photographic representation 
correlated with hormonal blood values. 
 
Vulvoscopy has been shown to be a useful tool in assessing the health and integrity of 
various genital organs including the glans clitoris, minor vestibular glands, labia minora and 
majora, peri-urethral tissue and vaginal mucosa. Women in menopause deprived of critical 
sex steroid hormones, estradiol and testosterone, often present with vulvoscopic findings of 
labial resorption, urethral meatal prolapse or telescoping of the urethral meatus, clitoral 
atrophy, vestibular erythema and tenderness, vestibular pallor, vestibulodynia and 
minimally robust peri-urethral tissue. It is hypothesized that with adherence and close 
monitoring, the hormonal menopausal management consisting of five strategies utilized at 
San Diego Sexual Medicine will lead to visible improvement on vulvoscopy.  Secondary 
objectives are to evaluate subjective responses to hormonal therapies using validated 
patient reported outcome score questionnaires.  
 
 
 
 
Abstract  
Objectives: Signs and symptoms of menopause associated with estradiol deficiency include 
dryness, burning, thinning, itching, urinary frequency and dyspareunia. Menopausal 
symptoms associated with testosterone deficiency include diminished sense of wellbeing, 
reduced muscle and bone mass, provoked vestibulodynia, and decreased sexual desire, 
arousability, and orgasmic pleasure. The hypothesisis is that with both high patient 
adherence and close health care provider monitoring, hormonal management will lead to 
subjective and objective improvements in signs and symptoms of genitourinary syndrome 
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of menopause (GSM). 
Materials and Methods: This study evaluated clinical benefit of hormonal replacement 
strategies for management of sexual dysfunction and GSM utilizing pre- and post-treatment 
blood test monitoring, FSFI scores and vulvoscopy findings. A chart review from August 1, 
2007 through December 1, 2015 was performed. Bioidentical hormonal therapy is designed 
to keep serum estradiol levels 35 - 50 pg/ml, serum progesterone levels at 1.0 ng/ml and 
calculated free testosterone levels at 0.8 ng/dl including daily topical vestibular and vaginal 
estradiol and testosterone applications. Subjects included were naturally or surgically peri-
menopausal or post-menopausal at their initial visit, with both an initial and at least one 
follow-up vulvoscopy. Exclusions included cosmetic vulvar or vestibular surgery.  
Results: 110 menopausal women (mean age 62 +/- 13 years) with sexual health complaints 
met study criteria.  Mean follow-up was 2.6 +/- 1.3 years. Pre-treatment vulvoscopic 
findings of resorption of labia minora, telescoping of the urethral meatus, clitoral atrophy, 
vestibular erythema, tenderness and pallor, minimally robust peri-urethral tissue, minimal 
vaginal rugae with thin, pale vaginal mucosa and abnormal vaginal pH were noted in 100%. 
In 81% of women, serum sex steroid values returned to ideal values. In 72% FSFI total 
scores increased more than 5 points. In 63% post-treatment vulvoscopic changes revealed 
pink, moist, pain-free vestibular tissue.                                                                                                                                          
Conclusion: Hormonal management of menopause with good patient adherence and close 
monitoring has lead to subjective and objective improvement of female sexual function 
 
 
 
KN age, 69 years, presented on 10/20/14 with vulvoscopic findings of labial resorption, 
telescoping of the urethral meatus, clitoral phimosis, vestibular erythema and tenderness, 
vestibular pallor, vestibulodynia and minimally robust peri-urethral tissue.  After use of the 
five biologically identical hormone treatment strategies, 10 months later, most of the 
vulvoscopic findings had changed, specifically the loss of the urethral telescoping, loss of 
pallor, loss of erythema.  In its place, pink moist pain-free vestibular tissue was noted. 
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Surgical Therapy for Vestibulodynia:  
 
Vestibulectomy is a procedure to remove the tender areas of the skin within the vestibule, 
typically the superficial layer. The hymen flap is then used to cover the small area where the 
involved skin surface was removed. Surgery has the best results for vulvar vestibulodynia, 
with reported cure rates around 85% for those refractory to other therapies. This 
procedure can be done in the office with local anesthesia or as a same day surgery. Usually 
physical therapy is necessary after surgery.  
 
 
 
Patient testimonial 
“I am a 41 year old female who first experienced sexual pain at the age of 26 after taking 
OCP. Sensuality became a huge part of my identity after discovering sex at the age of 20. 
Initially pain was intermittent and I only experienced it prior to my period. I went to see a 
multitude of doctors, who inevitably diagnosed yeast or bacterial infections and gave me 
antifungals or antibiotics. Sometimes the medications seemed to work but the pain always 
returned. I was tested for every STD known multiple times and the results were always 
negative. Once, out of frustration, I made an appointment with two different doctors in the 
same day and got two different diagnoses: yeast vaginosis and bacterial vaginosis. Several 
healthcare providers said there was nothing wrong with me, and seemed disgusted when 
that answer frustrated me. A nurse would ask, “Did you want something to be wrong?” as I 
replied, “No, but something IS wrong and all you’ve told me is that you haven’t found it.” 
One doctor suggested I spend more time on foreplay, another put his hand on my knee and 
earnestly said, “This is very important. I want you to go home tonight and have a glass of 
wine and have sex.” It was clear that her doctors believed the problem was primarily caused 
by a psychological issue. I developed a routine: make an appointment with a new doctor, 
feel hopeful, see the doctor, sit in the car afterwards and cry.  
 
At the age of 30 I saw a gynecologist who put me on a local topical estrogen, after which I 
had temporary relief of my symptoms for about 10 months. When a regimen of 200 mg of 
progesterone daily was added to regulate my menstrual cycle, within a month I developed 
severe, persistent vestibular pain. The pain did not go away even after stopping the 
progesterone. I started HRT but the pain remained constant. I began struggling with 
bitterness and despair, grieving the loss of intimacy and even my identity. I tried a variety of 
treatments: antifungals, antibiotics, steroid creams, amitriptyline, tegretol and Neurontin, 
cervical cryotherapy, acid treatment for HPV (which I didn’t have), HRT, local estrogen, 
vestibular biopsy for cancer (negative though showed inflammation), topical lidocaine, 
biofeedback, acupuncture, herbal remedies and emu oil. Over a span of 10 years I had spent 
more than $30,000 and seen more than 15 doctors.  
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Finally, a physical therapist sent me to see Dr. Goldstein, who was found through a 
community of women with similar symptoms who found a cure. Dr. Goldstein explained 
that the vestibular pain was a result of neuroproliferation, an overgrowth of pain-receiving 
nerves. The partial vestibulectomy hadn’t worked because my vestibular tissue needed to 
be removed in its entirety. In 2010, I underwent a total left and right anterior and posterior 
vestibulectomy with vaginal flap advancement. Remarkably, within 3 weeks the pain was 
lower than it had been pre-operatively even with stitches in place. Six months after surgery 
and beginning PT, the persistent and provoked vestibular pain was entirely gone. I was able 
to be intimate with my husband without pain.” 
 
 
Flibanserin 
 
Tuesday, August 18, 2015.  Flibanserin, a drug for acquired, generalized hypoactive sexual 
desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on 
August 18, 2015. This follows the June 4, 2015 meeting of their Advisory Committee whose 
members voted 18-6 for approval.  
 
This historic event marks the availability of the first pharmacologic treatment for women 
suffering from HSDD. It should be noted, and applauded, that the FDA recognizes female 
sexual disorders as one of their top 20 conditions for which there is unmet medical need 
and for making their decision to approve flibanserin based on science. I am optimistic that 
this approval will stimulate more research and drug development for HSDD and other 
female sexual disorders for which therapeutic options are greatly needed.  
 
Flibanserin will be marketed with the trade name Addyi. As of October 5, 2015, healthcare 
prescribers and pharmacies can complete training to become certified to prescribe or 
dispense the medication through the Addyi Risk Evaluation and Mitigation Strategy (REMS) 
Program. A REMS is a strategy to manage known or potential serious risks associated with a 
drug product and is required by the FDA to ensure the benefits of a drug outweigh its risks. 
The purpose of the Addyi REMS Program is to inform prescribers, outpatient pharmacies, 
inpatient pharmacies, and patients about the increased risk of hypotension and syncope due 
to an interaction with alcohol.  Before prescribing Addyi, prescribers must review and 
complete the Addyi REMS Patient-Provider Agreement Form with every patient, and keep 
the form in the patient file.  
 
Currently, SDSM is performing an unblinded study of flibanserin for 8 weeks with 
responders randomized 1:1 to receive study medication alone vs. study medication and sex 
therapy for an additional 12 weeks. Responders will be determined by a score of 1-3 on the 
Patient Global Impression of Improvement at 8 weeks from baseline. The primary objective 
of the study is to determine whether efficacy of flibanserin as determined by changes in the 
desire domain of the FSFI in women who respond to the study medication is greater when 
sex therapy is performed concomitant with the use of the medication.  
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SUMMARY AND PERSONAL REFLECTIONS 
 
The primary focus of my ISP was to gain clinical exposure on the multidisciplinary 
biopsychosocial evaluation of a woman presenting with a sexual health concern. Not only 
was I able to achieve this goal, but I also gained unique insight into the path that female 
patients take to seek care for their sexual dysfunction and the different perspectives and 
management approaches provided by a variety of specialists – ob/gyns, urologists, nurse 
practitioners, pelvic physical therapists, and sex therapists.  
 
My experience working with Dr. Goldstein, Dr. Macaulay, and Dr. Gross fueled my passion to 
explore the field of sexual medicine further throughout my medical training. As I enter the 
field of Obstetrics and Gynecology, I am passionate about bringing a humanistic, 
multidisciplinary approach to women’s reproductive health, destigmatizing sexual health 
topics and encouraging positive lifestyle habits. I feel a strong sense of purpose in treating 
the root cause of disease rather than focusing on symptomatic management, as I witnessed 
through my experiences. I look forward to working with a team of specialists to better 
identify the sources in a patient’s life which may be causing inflammation and address diet, 
nutrition, exercise, and meditation with my patients to optimize their health. Finally, I plan 
to advocate for sexual health education beginning early on in adolescence and ongoing 
education to physicians in training, with the additional goal of bringing awareness to a 
historically underserved patient population.  
 
I will conclude with a touching reflection that was shared with me by a patient. These 
powerful words highlight the necessity of our medical community to become aware about 
the prevalence of female sexual dysfunction and collaborate efforts to develop the field 
further.  
 
 “What patients with sexual dysfunction need is to be treated with dignity. We need the 
medical community to do research with a scientific approach, or use professional networks 
to refer patients to a specialist. We need the medical community to take these patients and 
their sexual health concerns seriously. The kinds of diseases these women are dealing with 
are not just quality of life issues, but lethal conditions. Imagine for a minute that you, you 
who are intelligent, of a sound mind and good mental health, you who love your body and 
maybe even a partner, you who love sex and can’t imagine life without it – imagine that you 
might never be able to have or share the sexual experience again because your vagina or 
penis burns with a constant, searing pain, as if with acid. Imagine that it hurts to sit, or wear 
jeans, or walk or dance. What if you could no longer work because you couldn’t tolerate 
sitting at a desk? What if your marriage were on the rocks? What would the face you 
presented to the world look after 5, 10, 20 years of this existence? Would you feel 
depressed, hopeless, angry? Would you feel like an outsider? Would you be suicidal? Would 
you think that it might perhaps be your best option, and the kindest to your long-suffering 
partner, if you were to take your own life? Those bothered by sexual pain have thought 
seriously about suicide. Please never doubt that this is a lethal, devastating condition.”  
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